» Articles » PMID: 18335393

A Comparison of the Levels of Hepatocyte Growth Factor in Serum in Patients with Type 1 Diabetes Mellitus with Different Stages of Diabetic Retinopathy

Overview
Journal Endokrynol Pol
Specialty Endocrinology
Date 2008 Mar 13
PMID 18335393
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The aim of this study was to evaluate the blood concentration of hepatocyte growth factor (HGF) in patients at various stages of retinopathy. We hypothesised that the high level of HGF found in diabetic patients may be an important marker of retinopathy progression and that HGF level may be an index of the risk of proliferative retinopathy.

Material And Methods: The participants in the study were 76 patients with type 1 diabetes mellitus. Of these, 35 patients were without retinopathy and formed Group 1. Of the remaining 41 patients with retinopathy, 20 patients had non-proliferative diabetic retinopathy (NPDR) and formed Group 2, while 21 patients had proliferative diabetic retinopathy (PDR) and formed Group 3. We evaluated the concentration of HGF In the peripheral blood by an enzyme-linked immunosorbent assay.

Results: Mean serum concentrations of HGF in the control group were significantly lower than in the type 1 diabetic patients. We found a significant increase in HGF serum concentrations in diabetic patients with PDR compared with the control group. Mean serum HGF concentrations were significantly higher in diabetic subjects with PDR than in diabetic patients without retinopathy.

Conclusion: HGF concentration is increased in patients with type 1 diabetes mellitus with proliferative retinopathy, and concentrations increase with the progression of retinopathy, suggesting that HGF plays a role in the pathogenesis of proliferative diabetic retinopathy.

Citing Articles

Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.

Nowak M, Sieminska L, Karpe J, Marek B, Kos-Kudla B, Kajdaniuk D J Endocrinol Invest. 2015; 39(1):63-72.

PMID: 26062519 PMC: 4703607. DOI: 10.1007/s40618-015-0322-7.


Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus.

Konya H, Miuchi M, Satani K, Matsutani S, Tsunoda T, Yano Y World J Diabetes. 2014; 5(5):678-88.

PMID: 25317245 PMC: 4138591. DOI: 10.4239/wjd.v5.i5.678.


Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy.

Nowak M, Wielkoszynski T, Marek B, Kos-Kudla B, Swietochowska E, Sieminska L Clin Exp Med. 2009; 10(3):185-92.

PMID: 20012460 DOI: 10.1007/s10238-009-0084-7.